in proinsulin and its possible physiological importance has been increasing (1, 2). An altered secretion of this beta-cell peptide might have pathophysiological significance (3,4) and may be a prognostic marker in the study of treatment of diabetes mellitus (5, 6). The detectionlimit of most proinsulin immunoassays is >1 pmol/L (7-10). In two recently described assays (11, 12), the detection limits were 0.1 and 0.8 pmol/L, respectively. However, enzyme amplification is needed in both assays. For analysis in patients with limited residual beta-cell function, as in insulin-dependent diabetes mellitus (10DM), highly sensitive and easily performed assays are needed.5
Materials and Methods

Materials
Antibodies. Available for absorbance at 620 nm. Controls and unknown samples were read on the calibrator curve.
For method comparison, we analyzed 49 consecutive sera with the present ELISA and compared the results with those obtained with our formerly described ELISA of hPI (7) .
Results and Discussion
Assay Optimization
Signal-to-noise ratios, defined as the signal obtained at 0.1 pmol/L hPI divided by the signal at zero dose, was used in optimization experiments.
Ratios <2 were considered insufficient. 
Assay Characteristics
We studied the binding capacity of the coating antibody in the presence of increasing C-peptide concentration. As shown in Figure 3 ELISAs. However, we found a linear dilution in both assays. Currently, therefore, we have no explanation to offer regarding this single discrepancy between the two methods.
In conclusion, by combining two high-affinity monoclonal antibodies against human C-peptide and human insulin in a simple sandwich ELISA,, we obtained a sufficiently low detection limit for measurement of serum PIM. Furthermore, the working range, 0.25-100
pmol/L in serum or plasma, is large enough to monitor PIM concentrations in sera from all fasting normal subjects as well as estimate pathologically increased concentrations. A minimum NM concentration in serum from fasting normals is demonstrated.
The assay seems therefore useful for studying circulating PIM concentrations in diabetic patients who have remaining beta-cell capacity. Compared with our previously described assay (7), the major advances are the use of monoclonal antibodies and a fivefold increase in sensitivity.
Recently described sensitive assays (11, 12) are based on the alkaline phosphatase amplification system (17); compared with these assays, the present assay is very simple to perform on a large scale. The method described by Alpha et al. (12) also depends on monoclonal antibodies.
The use of monodonal antibodies makes these assays widely applicable because of the availability of the antibodies on a large scale.
